目的 分析紫杉醇联合顺铂方案同步放疗对局部进展期宫颈癌患者的疗效及不良反应.方法 选取局部进展期宫颈癌患者68例,FIGOⅢ~Ⅳa期,接受根治性放疗,累积剂量为80 Gy,同时每周给予顺铂30 mg/m2+紫杉醇50 mg/m2.观察记录患者的疗效及不良反应.结果 68例患者的不良反应包括胃肠道损害、贫血及脑梗死等,2年累积远期不良反应发生率为25%.中位随访时间27个月,2年PFS为83.8%(75.1%~92.6%),2年OS为92.7%(86.4%~98.9%),2年DM为13.2%(5.2%~21.3%).结论 紫杉醇联合顺铂同步放疗治疗局部进展期宫颈癌的疗效显著,且方案安全可行.%Objective To assess the efficacy and adverse reactions of concurrent chemoradiotherapy with cisplatin and paclitaxel in patients with locally advanced cervical cancer. Method 68 cases of patients with locally advanced cer-vical cancer (FIGO stage Ⅲ-Ⅳa) were enrolled. These patients were given definitive radiotherapy with a cumulative dose of 80 Gy, and concurrently treated with 30 mg/m2 of cisplatin and 50 mg/m2 of paclitaxel once a week. The clinical effica-cy and adverse reactions were observed and recorded. Result The adverse reactions occurred in 68 patients included gas-trointestinal tract injuries, anemia and cerebral infarction. The 2-year long-term cumulative rate of adverse reactions was 25%, the median follow-up time was 27 months, the 2-year PFS was 83.8%(75.1%-92.6%), 2-year OS was 92.7%(86.4%-98.9%) and the 2-year DM was 13.2%(5.2%-21.3%). Conclusion The concurrent chemoradiotherapy with cisplatin and paclitaxel has shown significant effects in the treatment of patients with locally advanced cervical cancer, and the regimen is safe and feasible.
展开▼
